Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Net Margin: 2022-2025

Historic Net Margin for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to 165.14%.

  • InMed Pharmaceuticals' Net Margin fell 2150.00% to 154.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 171.13%, marking a year-over-year decrease of 3386.00%. This contributed to the annual value of 165.14% for FY2025, which is 180.00% up from last year.
  • According to the latest figures from FY2025, InMed Pharmaceuticals' Net Margin is 165.14%, which was up 1.08% from 166.94% recorded in FY2024.
  • InMed Pharmaceuticals' 5-year Net Margin high stood at 165.14% for FY2025, and its period low was 1,707.32% during FY2022.
  • Its 3-year average for Net Margin is 174.75%, with a median of 166.94% in 2024.
  • In the last 5 years, InMed Pharmaceuticals' Net Margin surged by 151,514bps in 2023 and then plummeted by 180bps in 2025.
  • InMed Pharmaceuticals' Net Margin (MRY) stood at 1,707.32% in 2022, then surged by 89bps to 192.18% in 2023, then grew by 13bps to 166.94% in 2024, then grew by 1bps to 165.14% in 2025.
  • Its Net Margin stands at 165.14% for FY2025, versus 166.94% for FY2024 and 192.18% for FY2023.